| 1 |
Shi ZD, Pang K, Wu ZX, Dong Y, Hao L, Qin JX, Wang W, Chen ZS, Han CH. Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduct Target Ther 2023;8:113. [PMID: 36906600 DOI: 10.1038/s41392-023-01383-x] [Reference Citation Analysis]
|
| 2 |
Huang P, Wang L, Wang Y, Tsai M, Lin T, Liao C, Yeh C, Lin K. Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer. Cells 2023;12:869. [DOI: 10.3390/cells12060869] [Reference Citation Analysis]
|
| 3 |
Li D, Huang S, Luo C, Xu Y, Fu S, Liu K, Wu J. CKLF as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma. Current Oncology 2023;30:2653-2672. [DOI: 10.3390/curroncol30030202] [Reference Citation Analysis]
|
| 4 |
Yang X, Chen B, Wang Y, Wang Y, Long J, Zhang N, Xue J, Xun Z, Zhang L, Cheng J, Lei J, Sun H, Li Y, Lin J, Xie F, Wang D, Pan J, Hu K, Guan M, Huo L, Shi J, Yu L, Zhou L, Zhou J, Lu Z, Yang X, Mao Y, Sang X, Lu Y, Zhao H. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients. Hepatol Int 2023;:1-11. [PMID: 36753026 DOI: 10.1007/s12072-022-10480-y] [Reference Citation Analysis]
|
| 5 |
Psilopatis I, Damaskos C, Garmpi A, Sarantis P, Koustas E, Antoniou EA, Dimitroulis D, Kouraklis G, Karamouzis MV, Vrettou K, Marinos G, Kontzoglou K, Garmpis N. FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? Int J Mol Sci 2023;24. [PMID: 36769004 DOI: 10.3390/ijms24032685] [Reference Citation Analysis]
|
| 6 |
Liang J, Bai Y, Ha FS, Luo Y, Deng HT, Gao YT. Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(1): 1-18 [PMID: 36684055 DOI: 10.4251/wjgo.v15.i1.1] [Reference Citation Analysis]
|
| 7 |
Lee YC, Huang WT, Lee MY, Tsao CJ, Feng YH. Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial. In Vivo 2023;37:454-60. [PMID: 36593061 DOI: 10.21873/invivo.13099] [Reference Citation Analysis]
|
| 8 |
Shao G, Bai Y, Yuan X, Chen X, Gu S, Gu K, Hu C, Liang H, Guo Y, Wang J, Yen CJ, Lee VH, Wang C, Widau RC, Zhang W, Liu J, Zhang Q, Qin S. Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study. EClinicalMedicine 2022;54:101679. [PMID: 36247923 DOI: 10.1016/j.eclinm.2022.101679] [Reference Citation Analysis]
|
| 9 |
Tu X, Yang J, Zheng Y, Liang C, Tao Q, Tang X, Liu Z, Jiang L, He Z, Xie F, Zheng Y. Immunotherapy combination with regorafenib for refractory hepatocellular carcinoma: A real-world study. International Immunopharmacology 2022;113:109401. [DOI: 10.1016/j.intimp.2022.109401] [Reference Citation Analysis]
|
| 10 |
Xian F, Wu C, Zhang G, Xu G. Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2022;101:e31479. [PMID: 36343054 DOI: 10.1097/MD.0000000000031479] [Reference Citation Analysis]
|
| 11 |
Zhu AX, Lin Y, Ferry D, Widau RC, Saha A. Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Immunotherapy 2022. [DOI: 10.2217/imt-2022-0089] [Reference Citation Analysis]
|
| 12 |
Li X, Zhang Q, Lu Q, Cheng Z, Liu F, Han Z, Yu X, Yu J, Liang P. Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1023983] [Reference Citation Analysis]
|
| 13 |
Li Q, Su T, Zhang X, Pan Y, Ma S, Zhang L, Zhang X, Gao X. A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma. Cancer Manag Res 2022;14:3037-46. [PMID: 36275784 DOI: 10.2147/CMAR.S379911] [Reference Citation Analysis]
|
| 14 |
Guan R, Yu C, Li S, Mei J, Wei W, Guo R. A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Front Pharmacol 2022;13:998534. [DOI: 10.3389/fphar.2022.998534] [Reference Citation Analysis]
|
| 15 |
Zhang L, Sun J, Wang K, Zhao H, Zhang X, Ren Z. First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review. Curr Oncol 2022;29:7305-26. [PMID: 36290852 DOI: 10.3390/curroncol29100575] [Reference Citation Analysis]
|
| 16 |
Liu Y, Liang W, Chang Y, He Z, Wu M, Zheng H, Ke X, Lv M, Liu Q, Liu Q, Tang W, Huang Q, Lu Y, He M, Yang Q, Mo C, Wang J, Peng K, Min Z, Su H, Chen J. CEP192 is a novel prognostic marker and correlates with the immune microenvironment in hepatocellular carcinoma. Front Immunol 2022;13:950884. [DOI: 10.3389/fimmu.2022.950884] [Reference Citation Analysis]
|
| 17 |
Qu W, Ding Z, Qu X, Tang Z, Zhu G, Fu X, Zhang Z, Zhang X, Huang A, Tang M, Tian M, Jiang X, Huang R, Tao C, Fang Y, Gao J, Wu X, Zhou J, Fan J, Liu W, Shi Y. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open 2022;6. [DOI: 10.1093/bjsopen/zrac114] [Reference Citation Analysis]
|
| 18 |
Li D, Xu L, Ji J, Bao D, Hu J, Qian Y, Zhou Y, Chen Z, Li D, Li X, Zhang X, Wang H, Yi C, Shi M, Pang Y, Liu S, Xu X. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study. Front Immunol 2022;13:944062. [DOI: 10.3389/fimmu.2022.944062] [Reference Citation Analysis]
|
| 19 |
Zhou M, Liu B, Shen J. Immunotherapy for hepatocellular carcinoma. Clin Exp Med 2022. [PMID: 36001163 DOI: 10.1007/s10238-022-00874-5] [Reference Citation Analysis]
|
| 20 |
Donne R, Lujambio A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology 2022. [PMID: 35989535 DOI: 10.1002/hep.32740] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 21 |
Huang S, Dong C, Zhang J, Fu S, Lv Y, Wu J. A comprehensive prognostic and immunological analysis of ephrin family genes in hepatocellular carcinoma. Front Mol Biosci 2022;9:943384. [DOI: 10.3389/fmolb.2022.943384] [Reference Citation Analysis]
|
| 22 |
Wang P, Yang X, Liu D, Yang Y, Zhang Y, Wang G. Construction of a competing endogenous RNA network to analyse glucose-6-phosphate dehydrogenase dysregulation in hepatocellular carcinoma. Biosci Rep 2022;42:BSR20220674. [PMID: 35712981 DOI: 10.1042/BSR20220674] [Reference Citation Analysis]
|
| 23 |
Chen X, Lin L, Chen G, Yan H, Li Z, Xiao M, He X, Zhang F, Zhang Y. High Levels of DEAH-Box Helicases Relate to Poor Prognosis and Reduction of DHX9 Improves Radiosensitivity of Hepatocellular Carcinoma. Front Oncol 2022;12:900671. [DOI: 10.3389/fonc.2022.900671] [Reference Citation Analysis]
|
| 24 |
Wang G, Zhang W, Chen J, Luan X, Wang Z, Wang Y, Xu X, Yao S, Guan Z, Tian J, Lu S, Xu B, Ma G. Pretreatment Metabolic Parameters Measured by 18F-FDG PET to Predict the Pathological Treatment Response of HCC Patients Treated With PD-1 Inhibitors and Lenvatinib as a Conversion Therapy in BCLC Stage C. Front Oncol 2022;12:884372. [PMID: 35719917 DOI: 10.3389/fonc.2022.884372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Jiang Q, Huang J, Zhang B, Li X, Chen X, Cui B, Li S, Guo G. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis. Front Immunol 2022;13:801909. [PMID: 35309350 DOI: 10.3389/fimmu.2022.801909] [Reference Citation Analysis]
|
| 26 |
Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer 2022;10:e004656. [DOI: 10.1136/jitc-2022-004656] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 27 |
Tao ZW, Cheng BQ, Zhou T, Gao YJ. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review. Hepatobiliary Pancreat Dis Int 2022;21:134-44. [PMID: 34955380 DOI: 10.1016/j.hbpd.2021.12.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 28 |
Jiang Y, Cai D, Shi S. Indirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies. CLEP 2022;Volume 14:581-90. [DOI: 10.2147/clep.s352045] [Reference Citation Analysis]
|
| 29 |
Abdelrahim M, Esmail A, Saharia A, Abudayyeh A, Abdel-Wahab N, Diab A, Murakami N, Kaseb AO, Chang JC, Gaber AO, Ghobrial RM. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. Cancers (Basel) 2022;14:1760. [PMID: 35406533 DOI: 10.3390/cancers14071760] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 30 |
Himmelsbach V, Pinter M, Scheiner B, Venerito M, Sinner F, Zimpel C, Marquardt JU, Trojan J, Waidmann O, Finkelmeier F. Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers. Cancers (Basel) 2022;14:1722. [PMID: 35406493 DOI: 10.3390/cancers14071722] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 31 |
Wu Y, Lin H, You X, Guo T, Sun T, Xu H, Fu X. Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity. Front Oncol 2022;12:764923. [DOI: 10.3389/fonc.2022.764923] [Reference Citation Analysis]
|
| 32 |
Cheon J, Yoo C, Hong JY, Kim HS, Lee DW, Lee MA, Kim JW, Kim I, Oh SB, Hwang JE, Chon HJ, Lim HY. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. Liver Int 2022;42:674-81. [PMID: 34792284 DOI: 10.1111/liv.15102] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 33 |
Shen J, Shen H, Ke L, Chen J, Dang X, Liu B, Hua Y. Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. Front Immunol 2022;13:815575. [DOI: 10.3389/fimmu.2022.815575] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 34 |
Lu L, Zhan M, Li X, Zhang H, Dauphars DJ, Jiang J, Yin H, Li S, Luo S, Li Y, He Y. Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Current Research in Immunology 2022;3:118-27. [DOI: 10.1016/j.crimmu.2022.05.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 35 |
Xu S, Lai R, Zhao Q, Zhao P, Zhao R, Guo Z. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Front Immunol 2021;12:794099. [PMID: 34950153 DOI: 10.3389/fimmu.2021.794099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 36 |
Zhang VX, Sze KM, Chan L, Ho DW, Tsui Y, Chiu Y, Lee E, Husain A, Huang H, Tian L, Wong CC, Ng IO. Antioxidant supplements promote tumor formation and growth and confer drug resistance in hepatocellular carcinoma by reducing intracellular ROS and induction of TMBIM1. Cell Biosci 2021;11. [DOI: 10.1186/s13578-021-00731-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
